- Home
- SEMR vs EWTX Comparison
SEMR vs EWTX Comparison
Compare SEMR & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEMR
- EWTX
- Stock Information
- Founded
- SEMR 2008
- EWTX 2017
- Country
- SEMR United States
- EWTX United States
- Employees
- SEMR N/A
- EWTX N/A
- Industry
- SEMR EDP Services
- EWTX Biotechnology: Pharmaceutical Preparations
- Sector
- SEMR Technology
- EWTX Health Care
- Exchange
- SEMR Nasdaq
- EWTX Nasdaq
- Market Cap
- SEMR 1.3B
- EWTX 1.5B
- IPO Year
- SEMR 2021
- EWTX 2021
- Fundamental
- Price
- SEMR $9.82
- EWTX $14.31
- Analyst Decision
- SEMR Buy
- EWTX Buy
- Analyst Count
- SEMR 8
- EWTX 9
- Target Price
- SEMR $17.00
- EWTX $39.89
- AVG Volume (30 Days)
- SEMR 833.4K
- EWTX 712.9K
- Earning Date
- SEMR 08-04-2025
- EWTX 08-07-2025
- Dividend Yield
- SEMR N/A
- EWTX N/A
- EPS Growth
- SEMR N/A
- EWTX N/A
- EPS
- SEMR 0.05
- EWTX N/A
- Revenue
- SEMR $396,021,000.00
- EWTX N/A
- Revenue This Year
- SEMR $21.85
- EWTX N/A
- Revenue Next Year
- SEMR $18.50
- EWTX N/A
- P/E Ratio
- SEMR $206.70
- EWTX N/A
- Revenue Growth
- SEMR 22.75
- EWTX N/A
- 52 Week Low
- SEMR $7.90
- EWTX $10.60
- 52 Week High
- SEMR $18.74
- EWTX $38.12
- Technical
- Relative Strength Index (RSI)
- SEMR 57.65
- EWTX 44.98
- Support Level
- SEMR $8.60
- EWTX $13.34
- Resistance Level
- SEMR $10.10
- EWTX $14.08
- Average True Range (ATR)
- SEMR 0.28
- EWTX 0.52
- MACD
- SEMR 0.12
- EWTX 0.06
- Stochastic Oscillator
- SEMR 68.32
- EWTX 52.51
About SEMR SEMrush Holdings Inc.
SEMrush Holdings Inc is engaged in the online visibility management software-as-a-service (SaaS) platform. Its platform utilizes data and intelligence at the core surrounded by AI-powered interconnected hubs focused on search engine optimization, paid advertising, social media management, local marketing, brand marketing, and content marketing Geographically, it generates revenues from the United States, the UK, and Others.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.